WO2017125060A1 - 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 - Google Patents
一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 Download PDFInfo
- Publication number
- WO2017125060A1 WO2017125060A1 PCT/CN2017/071821 CN2017071821W WO2017125060A1 WO 2017125060 A1 WO2017125060 A1 WO 2017125060A1 CN 2017071821 W CN2017071821 W CN 2017071821W WO 2017125060 A1 WO2017125060 A1 WO 2017125060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- alkyl
- methyl
- ethyl
- Prior art date
Links
- 0 CC(CCN(CC1)CCC1OC(N*)=O)=O Chemical compound CC(CCN(CC1)CCC1OC(N*)=O)=O 0.000 description 6
- OETHHQHPNSEEQH-BHVANESWSA-N CN(CCNC[C@@H](c(cc1)c(C=CC(N2)=O)c2c1O)O)C(C(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O Chemical compound CN(CCNC[C@@H](c(cc1)c(C=CC(N2)=O)c2c1O)O)C(C(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O OETHHQHPNSEEQH-BHVANESWSA-N 0.000 description 2
- UOZWGNJJINDUFM-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(COC(Nc2ccc(C3OCCO3)cc2)=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(COC(Nc2ccc(C3OCCO3)cc2)=O)CC1)=O UOZWGNJJINDUFM-UHFFFAOYSA-N 0.000 description 1
- IXGITEDMTGMVID-LBPRGKRZSA-N CC(C)(C)OC(N1C[C@@H](COC(Nc2cc(OC)c(C=O)cc2Cl)=O)CC1)=O Chemical compound CC(C)(C)OC(N1C[C@@H](COC(Nc2cc(OC)c(C=O)cc2Cl)=O)CC1)=O IXGITEDMTGMVID-LBPRGKRZSA-N 0.000 description 1
- IUXAKNCOGGLQQH-XMMPIXPASA-N COc(c(C=O)c1)cc(NC(OC[C@H](CC2)CN2C(CCN(CC2)CCC2OC(Nc(cccc2)c2-c2ccccc2)=O)=O)=O)c1Cl Chemical compound COc(c(C=O)c1)cc(NC(OC[C@H](CC2)CN2C(CCN(CC2)CCC2OC(Nc(cccc2)c2-c2ccccc2)=O)=O)=O)c1Cl IUXAKNCOGGLQQH-XMMPIXPASA-N 0.000 description 1
- OTLUWOAZTKBFSV-FAIXQHPJSA-N COc(cc1NC(OC(CC2)CCN2C(CCN(CC2)CCC2OC(Nc2ccccc2-c2ccccc2)=O)=O)=O)c(CNC[C@@H](c(cc2)c(C=CC(N3)=O)c3c2O)O)cc1Cl Chemical compound COc(cc1NC(OC(CC2)CCN2C(CCN(CC2)CCC2OC(Nc2ccccc2-c2ccccc2)=O)=O)=O)c(CNC[C@@H](c(cc2)c(C=CC(N3)=O)c3c2O)O)cc1Cl OTLUWOAZTKBFSV-FAIXQHPJSA-N 0.000 description 1
- BKMCHBDACJPUPU-VIFPVBQESA-N COc(cc1NC(OC[C@@H]2CNCC2)=O)c(C=O)cc1Cl Chemical compound COc(cc1NC(OC[C@@H]2CNCC2)=O)c(C=O)cc1Cl BKMCHBDACJPUPU-VIFPVBQESA-N 0.000 description 1
- GLJTWBBYONKLSX-UHFFFAOYSA-N N#Cc(cc1)cc(F)c1NC(OCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O Chemical compound N#Cc(cc1)cc(F)c1NC(OCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O GLJTWBBYONKLSX-UHFFFAOYSA-N 0.000 description 1
- GJSFRUWKKVRUAZ-UHFFFAOYSA-N O=Cc(cc1)ccc1NC(OCC1CCNCC1)=O Chemical compound O=Cc(cc1)ccc1NC(OCC1CCNCC1)=O GJSFRUWKKVRUAZ-UHFFFAOYSA-N 0.000 description 1
- LFMDTPFPRWYPBO-UHFFFAOYSA-N OC(CNCc(cc1)ccc1C(NCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O)c(c(C=C1)c2NC1=O)ccc2O Chemical compound OC(CNCc(cc1)ccc1C(NCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc(cccc1)c1-c1ccccc1)=O)=O)=O)c(c(C=C1)c2NC1=O)ccc2O LFMDTPFPRWYPBO-UHFFFAOYSA-N 0.000 description 1
- YZSVQQJSQWUNCC-UHFFFAOYSA-N OC(CNCc(cc1)ccc1NC(OCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc1ccccc1-c1ccccc1)=O)=O)=O)c(c(C=C1)c2NC1=O)ccc2O Chemical compound OC(CNCc(cc1)ccc1NC(OCC(CC1)CCN1C(CCN(CC1)CCC1OC(Nc1ccccc1-c1ccccc1)=O)=O)=O)c(c(C=C1)c2NC1=O)ccc2O YZSVQQJSQWUNCC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
实施例编号 | hM3受体IC50(nM) |
化合物1 | 14.44 |
化合物2 | 1.69 |
化合物3 | 3.76 |
化合物4 | 2.26 |
化合物5 | 0.89 |
化合物6 | 6.49 |
化合物7 | 1.31 |
化合物8 | 3.33 |
化合物9 | 3.73 |
实施例编号 | hβ2受体EC50(nM) |
化合物2 | 1.85 |
化合物3 | 10.21 |
化合物6 | 17.41 |
化合物7 | 6.01 |
化合物8 | 3.34 |
化合物9 | 3.96 |
Claims (15)
- 一种通式(I)所示的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,其中:环C1和环C2各自独立的选自C6-10碳环或5至10元杂环,所述碳环或杂环任选进一步被0至5个选自F、Cl、Br、I、CF3、NH2、OH、羧基、氰基、C1-4烷基、C1-4烷氧基、C1-4烷硫基、-NHC1-4烷基、-N(C1-4烷基)2、-S(=O)-C1-4烷基、-S(=O)2-C1-4烷基或-C(=O)O-C1-4烷基的取代基所取代,且所述杂环含有1至3个选自N、O或S的杂原子;环C3选自4至7元含氮杂环,且所述的含氮杂环任选进一步被0至4个选自F、Cl、Br、I、OH、氰基、CF3、C1-4烷基或C1-4烷氧基的取代基所取代,且所述含氮杂环含有1至3个选自N、O或S的杂原子;R2选自键或C1-4亚烷基,所述亚烷基任选进一步被0至5个选自F、Cl、Br、I、OH、氰基、C1-4烷基或C1-4烷氧基的取代基所取代;X选自键、-O-、-C(=O)O-、-OC(=O)-、-S-、-S(=O)-、-S(=O)2-、-C(=O)NRx-、-NRxC(=O)-、-OC(=O)NRx-、-NRxC(=O)O-、-NRxC(=O)NRx-、-NRxS(=O)2-、-S(=O)2NRx-、-NRxS(=O)2NRx-或-NRx-;Rx各自独立选自H或者C1-4烷基;A选自键、C6-10碳环或5至10元杂环,所述的碳环或杂环任选进一步被0至5个RA取代,且所述杂环含有1至4个选自N、O或S的杂原子;RA选自F、Cl、Br、I、OH、NH2、羧基、氰基、硝基、(=O)、C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、-OC3-6环烷基、C1-4烷硫基、-S(=O)-C1-4烷基、-S(=O)2-C1-4烷基、-C(=O)-C1-4烷基、-C(=O)O-C1-4烷基、-OC(=O)-C1-4烷基、5至6元杂芳基或-C(=O)NH2,所述烷基、烷氧基、环烷基、烯基、炔基、杂芳基、NH2和-C(=O)NH2任选进一步被0至4个选自F、Cl、Br、I、CF3、C1-4烷基、C1-4烷氧基或-C(=O)-C1-4烷基的取代基所取 代;R3选自C1-6亚烷基,所述亚烷基任选进一步被0至5个选自R3a的取代基所取代;R3a选自F、Cl、Br、I、氰基、OH、C1-4烷基、C1-4烷氧基、苯基或苯基-C1-4亚烷基;作为选择,两个R3a可以与它们相连的原子一起形成一个3至6元碳环,所述碳环任选进一步被0至5个选自F、Cl、Br、I、氰基、OH、C1-4烷基或C1-4烷氧基的取代基所取代;R4、R5各自独立的选自H或C1-4烷基;
- 根据权利要求2所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药:环C1和环C2各自独立的选自C6-10碳环或5至10元杂环,所述碳环或杂环任选进一步被0至5个选自F、Cl、Br、I、CF3、NH2、OH、氰基、C1-4烷基、C1-4烷氧基、C1-4烷硫基、-NHC1-4烷基或-N(C1-4烷基)2取代基所取代,且所述杂环含有1至3个选自N、O或S的杂原子;RA各自独立选自F、Cl、Br、I、OH、NH2、羧基、氰基、(=O)、C1-4烷基、C2-4炔基、C1-4烷氧基、-OC3-6环烷基或C1-4烷硫基,所述烷基、炔基、烷氧基、环烷基和NH2任选进一步被0至4个选自F、Cl、Br、I、CF3、C1-4烷基、C1-4烷氧基或-C(=O)-C1-4烷基的取代基所取代。
- 根据权利要求3所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,其中:环C1和环C2各自独立的选自苯环、噻吩环、噻唑环、异噻唑环、呋喃环、噁唑环、异噁唑环、吡咯环、咪唑环、吡啶环、苯并噻吩环、苯并噻唑环、苯并呋喃环或苯并噁唑环,所述苯环、噻吩环、噻唑环、异噻唑环、呋喃环、噁唑环、异噁唑环、吡咯环、咪唑环、吡啶环、苯并噻吩环、苯并噻唑环、苯并呋喃环或苯并噁唑环任选进一步被0至5个选自F、Cl、Br、I、CF3、NH2、OH、氰基、C1-4烷基、C1-4烷氧基、C1-4烷硫基、-NHC1-4烷基或-N(C1-4烷基)2的取代基所取代;环C3选自4至7元含氮杂环,所述的含氮杂环任选进一步被0至4个选自F、Cl、Br、I、CF3、甲基或乙基的取代基所取代,且所述含氮杂环含有1至3个选自N、O或S的杂原子;R2选自键、亚甲基、亚乙基或亚丙基,所述的亚甲基、亚乙基或亚丙基任选进一步被0至5个选自F、Cl、Br、I、氰基、OH、甲基、乙基、甲氧基或乙氧基的取代基所取代;A选自键、亚苯基或亚吡啶基,所述的亚苯基、亚吡啶基任选进一步被0至4个选自F、Cl、Br、氰基、甲基、乙基、丙基、异丙基、CHF2、CF3、甲氧基、乙氧基、-OCHF2、-OCF3、乙炔基或丙炔基的取代基所取代;X选自键、-O-、-C(=O)NRx-、-NRxC(=O)-、-OC(=O)NRx-或-NRxC(=O)O-;Rx选自H、甲基、乙基或者丙基;R4、R5各自独立的选自H、甲基或乙基;
- 根据权利要求4所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,其中:R2选自键、亚甲基、亚乙基或亚丙基;R3选自亚甲基、亚乙基、亚丙基、-CH2CH(CH3)-、-CH(CH3)CH2-、-CH2C(CH3)2-、-C(CH3)2CH2-、亚丁基、-CH(CH3)CH2CH2-、-CH2CH(CH3)CH2-、-CH2CH(CH3)CH2-、或亚戊基;A选自键、亚苯基或亚吡啶基,所述的亚苯基或亚吡啶基任选进一步被0至4个任选自F、Cl、Br、CHF2、CF3、氰基、甲基、乙基、甲氧基、乙氧基、-OCHF2、-OCF3、乙炔基或丙炔基的取代基所取代。
- 一种药物组合物,所述的药物组合物含有治疗有效剂量的根据利要求1~7中任一项所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,以及药学上可接受的载体、稀释剂、佐剂、媒介物或赋形剂;所述的 组合物还可进一步包括一种或多种其他治疗剂。
- 根据权利要求8所述的药物组合物,其中所述其他治疗剂选自PDE4抑制剂、M受体拮抗剂、皮质类固醇和β-肾上腺素受体激动剂中的一种或多种。
- 权利要求1-7任一项所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,或权利要求8-9任一项所述的药物组合物在制备用于治疗气道阻塞性疾病的药物中的应用。
- 根据权利要求10所述的应用,所述的气道阻塞性疾病选自哮喘、慢性阻塞性肺疾病或支气管炎。
- 一种治疗气道阻塞性疾病的方法,所述方法包括给药权利要求1~7中任一项所述的化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或前药,或权利要求8或9所述的药物组合物。
- 根据权利要求12所述的方法,所述的气道阻塞性疾病选自哮喘、慢性阻塞性肺疾病或支气管炎。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187005461A KR20180100106A (ko) | 2016-01-22 | 2017-01-20 | 질소함유 헤테로 고리 아미드 유도체 및 그 제조방법과 약학적 용도 |
EP17741091.7A EP3406606A4 (en) | 2016-01-22 | 2017-01-20 | HETEROCYCLIC NITROGEN AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHRAMACEUTICAL APPLICATION |
CN201780002426.2A CN107849019A (zh) | 2016-01-22 | 2017-01-20 | 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 |
AU2017209340A AU2017209340A1 (en) | 2016-01-22 | 2017-01-20 | Azacycle amide derivative, preparation method thereof, and pharmaceutical application |
BR112018015018A BR112018015018A2 (pt) | 2016-01-22 | 2017-01-20 | derivado de amido azaciclo, método de preparação deste, e aplicação farmacêutica |
EA201891682A EA201891682A1 (ru) | 2016-01-22 | 2017-01-20 | Производное азациклического амида, способ его получения и фармацевтическое применение |
JP2018536235A JP2019504069A (ja) | 2016-01-22 | 2017-01-20 | 窒素含有複素環アミド誘導体及びその製造方法、並びに医薬上の用途 |
MX2018008799A MX2018008799A (es) | 2016-01-22 | 2017-01-20 | Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica. |
CA3010660A CA3010660A1 (en) | 2016-01-22 | 2017-01-20 | Nitrogenous heterocyclic amide derivative, preparation method thereof, and pharmaceutical application |
US16/070,609 US20210205291A1 (en) | 2016-01-22 | 2017-01-20 | Nitrogenous heterocyclic amide derivative, preparation method thereof, and pharmaceutical application |
HK18106265.5A HK1246785A1 (zh) | 2016-01-22 | 2018-05-15 | 一種氮雜環酰胺衍生物及其製備方法和在醫藥上的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610046089.4 | 2016-01-22 | ||
CN201610046089 | 2016-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017125060A1 true WO2017125060A1 (zh) | 2017-07-27 |
Family
ID=59361427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/071821 WO2017125060A1 (zh) | 2016-01-22 | 2017-01-20 | 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210205291A1 (zh) |
EP (1) | EP3406606A4 (zh) |
JP (1) | JP2019504069A (zh) |
KR (1) | KR20180100106A (zh) |
CN (1) | CN107849019A (zh) |
AU (1) | AU2017209340A1 (zh) |
BR (1) | BR112018015018A2 (zh) |
CA (1) | CA3010660A1 (zh) |
EA (1) | EA201891682A1 (zh) |
HK (1) | HK1246785A1 (zh) |
MX (1) | MX2018008799A (zh) |
TW (1) | TW201730150A (zh) |
WO (1) | WO2017125060A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019015639A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物组合物及其制备 |
WO2019015640A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途 |
CN111423434A (zh) * | 2019-01-09 | 2020-07-17 | 四川海思科制药有限公司 | 一种碳酰胺衍生物及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021110076A1 (zh) * | 2019-12-04 | 2021-06-10 | 深圳信立泰药业股份有限公司 | 草酰胺类衍生物、其制备方法及其在医药上的应用 |
EP4086258A4 (en) * | 2019-12-31 | 2023-11-29 | Chengdu Baiyu Pharmaceutical Co., Ltd. | PURINE DERIVATIVE AND MEDICAL USE THEREOF |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1759108A (zh) * | 2003-02-14 | 2006-04-12 | 施万制药 | 联苯衍生物 |
CN1882556A (zh) * | 2003-11-21 | 2006-12-20 | 施万制药 | 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
SI2599778T1 (sl) * | 2009-04-23 | 2017-08-31 | Theravance Respiratory Company, Llc | Diamidne spojine, ki imajo muskarinski receptor-antagonistično in beta 2 adrenergični receptor-agonistično aktivnost |
-
2017
- 2017-01-20 TW TW106102062A patent/TW201730150A/zh unknown
- 2017-01-20 US US16/070,609 patent/US20210205291A1/en not_active Abandoned
- 2017-01-20 KR KR1020187005461A patent/KR20180100106A/ko unknown
- 2017-01-20 AU AU2017209340A patent/AU2017209340A1/en not_active Abandoned
- 2017-01-20 EA EA201891682A patent/EA201891682A1/ru unknown
- 2017-01-20 CA CA3010660A patent/CA3010660A1/en not_active Abandoned
- 2017-01-20 WO PCT/CN2017/071821 patent/WO2017125060A1/zh active Application Filing
- 2017-01-20 CN CN201780002426.2A patent/CN107849019A/zh active Pending
- 2017-01-20 BR BR112018015018A patent/BR112018015018A2/pt not_active Application Discontinuation
- 2017-01-20 JP JP2018536235A patent/JP2019504069A/ja active Pending
- 2017-01-20 EP EP17741091.7A patent/EP3406606A4/en not_active Withdrawn
- 2017-01-20 MX MX2018008799A patent/MX2018008799A/es unknown
-
2018
- 2018-05-15 HK HK18106265.5A patent/HK1246785A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1759108A (zh) * | 2003-02-14 | 2006-04-12 | 施万制药 | 联苯衍生物 |
CN1882556A (zh) * | 2003-11-21 | 2006-12-20 | 施万制药 | 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3406606A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019015639A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物组合物及其制备 |
WO2019015640A1 (zh) * | 2017-07-21 | 2019-01-24 | 四川海思科制药有限公司 | 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途 |
CN111423434A (zh) * | 2019-01-09 | 2020-07-17 | 四川海思科制药有限公司 | 一种碳酰胺衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20180100106A (ko) | 2018-09-07 |
EA201891682A1 (ru) | 2018-12-28 |
AU2017209340A1 (en) | 2018-07-05 |
HK1246785A1 (zh) | 2018-09-14 |
BR112018015018A2 (pt) | 2018-12-18 |
CN107849019A (zh) | 2018-03-27 |
CA3010660A1 (en) | 2017-07-27 |
EP3406606A1 (en) | 2018-11-28 |
JP2019504069A (ja) | 2019-02-14 |
US20210205291A1 (en) | 2021-07-08 |
TW201730150A (zh) | 2017-09-01 |
EP3406606A4 (en) | 2019-06-26 |
MX2018008799A (es) | 2019-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2314306C2 (ru) | Производные хинуклидинамида, способ их получения и их применение, фармацевтическая композиция, комбинированный продукт и способ ингибирования мускариновых рецепторов | |
WO2017125060A1 (zh) | 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途 | |
RU2412183C2 (ru) | Производные пирролидиния в качестве мускариновых рецепторов м3 | |
US20100105661A1 (en) | Condensed pyridine compound | |
TW201336833A (zh) | 激酶抑制劑 | |
EA021755B1 (ru) | ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ | |
AU2005262330A1 (en) | Piperidine derivatives as NK1 antagonists | |
BG107950A (bg) | Нови хинуклидинови производни и медицински състави, които ги съдържат | |
JP2008525359A (ja) | M3アンタゴニストとしての第4級アンモニウム塩類 | |
EA009942B1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
TW201708211A (zh) | 具有 β 2受體激動及M3受體拮抗活性的苯並環衍生物及其在醫藥上的用途 | |
WO2016180349A1 (zh) | 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途 | |
CN107849008B (zh) | 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途 | |
JP2006522787A (ja) | ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体 | |
KR20200020910A (ko) | 벤즈아제핀 유도체 | |
RU2611627C2 (ru) | Алкалоидный эфир и карбаматные производные и их медицинские композиции | |
WO2016155573A1 (zh) | 一种杂环衍生物及其制备方法和在医药上的用途 | |
JP2007507496A (ja) | ムスカリン受容体アンタゴニストとしての1−(アルキルアミノアルキル−ピロリジン−/ピペリジニル)−2,2−ジフェニルアセタミド誘導体 | |
TW201702225A (zh) | 具有β2受體激動及M受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途 | |
CN110590776A (zh) | 一种联苯衍生物及其制备方法和在医药上的用途 | |
WO2019015640A1 (zh) | 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途 | |
WO2017114377A1 (zh) | 一种苯基杂环衍生物及其在医药上的用途 | |
WO2017107877A1 (zh) | 一种联苯衍生物及其制备方法和在医药上的用途 | |
WO2018059537A1 (zh) | 一种二氮杂螺[5.5]十一碳烷衍生物及其用途 | |
CN111574529A (zh) | 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17741091 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20187005461 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017209340 Country of ref document: AU Date of ref document: 20170120 Kind code of ref document: A Ref document number: 3010660 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018536235 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/008799 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018015018 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201891682 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017741091 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017741091 Country of ref document: EP Effective date: 20180822 |
|
ENP | Entry into the national phase |
Ref document number: 112018015018 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180723 |